Related Experiment Video
Updated: Jul 29, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Liquid Chromatography-Tandem Mass Spectrometry Analysis Demonstrates a Decrease in Porins and Increase in CMY-2
Dimard E Foudraine1, Camiel N M Aarents1, Agnes A Wattel1
1Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center (Erasmus MC), Rotterdam, Netherlands.
Abstract:
While Extended-Spectrum β-Lactamases (ESBL) and AmpC β-lactamases barely degrade carbapenem antibiotics, they are able to bind carbapenems and prevent them from interacting with penicillin-binding proteins, thereby inhibiting their activity. Further, it has been shown that Enterobacterales can become resistant to carbapenems when high concentrations of ESBL and AmpC β-lactamases are present in the bacterial cell in combination with a decreased influx of antibiotics (due to a decrease in porins and outer-membrane permeability). In this study, a targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed for the detection of the Escherichia coli porins OmpC and OmpF, its chromosomal AmpC β-lactamase, and the plasmid-mediated CMY-2 β-lactamase. Bla CMY-2-like positive E. coli isolates were cultured in the presence of increasing concentrations of meropenem, and resistant mutants were analyzed using the developed LC-MS/MS assay, Western blotting, and whole genome sequencing. In five strains that became meropenem resistant, a decrease in OmpC and/or OmpF (caused by premature stop codons or gene interruptions) was the first event toward meropenem resistance. In four of these strains, an additional increase in MICs was caused by an increase in CMY-2 production, and in one strain this was most likely caused by an increase in CTX-M-15 production. The LC-MS/MS assay developed proved to be suitable for the (semi-)quantitative analysis of CMY-2-like β-lactamases and porins within 4 h. Targeted LC-MS/MS could have additional clinical value in the early detection of non-carbapenemase-producing carbapenem-resistant E. coli.
Insights
Extended-Spectrum β-Lactamases (ESBL) and AmpC β-lactamases contribute to carbapenem resistance in E. coli. Decreased porin expression is an early resistance mechanism, detectable by LC-MS/MS.
Area of Science:
- Microbiology
- Biochemistry
- Genetics
Background:
- Extended-Spectrum β-Lactamases (ESBL) and AmpC β-lactamases can confer carbapenem resistance in Enterobacterales.
- Mechanisms include binding carbapenems and reduced antibiotic influx due to decreased porin expression.
Purpose of the Study:
- Develop a targeted LC-MS/MS assay for detecting E. coli porins (OmpC, OmpF), AmpC β-lactamase, and CMY-2 β-lactamase.
- Investigate early resistance mechanisms to meropenem in E. coli.
Main Methods:
- Targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay development.
- Culturing E. coli isolates with increasing meropenem concentrations.
- Analysis of resistant mutants using LC-MS/MS, Western blotting, and whole genome sequencing.
Main Results:
- Decreased OmpC and/or OmpF expression was the initial step towards meropenem resistance in five strains.
- Increased CMY-2 production contributed to higher Minimum Inhibitory Concentrations (MICs) in four strains.
- One strain showed increased resistance likely due to elevated CTX-M-15 production.
Conclusions:
- The developed LC-MS/MS assay is effective for (semi-)quantitative analysis of CMY-2-like β-lactamases and porins within 4 hours.
- Targeted LC-MS/MS holds clinical value for early detection of non-carbapenemase-producing carbapenem-resistant E. coli.

